Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Change in Acquisitions & Divestments: 2019-2025

Historic Change in Acquisitions & Divestments for C4 Therapeutics (CCCC) over the last 5 years, with Sep 2025 value amounting to $51.2 million.

  • C4 Therapeutics' Change in Acquisitions & Divestments fell 25.52% to $51.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $221.2 million, marking a year-over-year decrease of 11.09%. This contributed to the annual value of $233.2 million for FY2024, which is 19.56% down from last year.
  • Per C4 Therapeutics' latest filing, its Change in Acquisitions & Divestments stood at $51.2 million for Q3 2025, which was down 15.80% from $60.8 million recorded in Q2 2025.
  • C4 Therapeutics' 5-year Change in Acquisitions & Divestments high stood at $115.0 million for Q1 2021, and its period low was $51.2 million during Q3 2025.
  • Moreover, its 3-year median value for Change in Acquisitions & Divestments was $60.8 million (2025), whereas its average is $62.7 million.
  • Within the past 5 years, the most significant YoY rise in C4 Therapeutics' Change in Acquisitions & Divestments was 44.85% (2022), while the steepest drop was 37.05% (2022).
  • Over the past 5 years, C4 Therapeutics' Change in Acquisitions & Divestments (Quarterly) stood at $86.1 million in 2021, then decreased by 22.12% to $67.1 million in 2022, then increased by 4.35% to $70.0 million in 2023, then decreased by 22.19% to $54.5 million in 2024, then fell by 25.52% to $51.2 million in 2025.
  • Its last three reported values are $51.2 million in Q3 2025, $60.8 million for Q2 2025, and $54.8 million during Q1 2025.